These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 29535422)

  • 1. The HER4-YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition.
    Shi J; Li F; Yao X; Mou T; Xu Z; Han Z; Chen S; Li W; Yu J; Qi X; Liu H; Li G
    Oncogene; 2018 May; 37(22):3022-3038. PubMed ID: 29535422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo.
    Sun D; Li X; He Y; Li W; Wang Y; Wang H; Jiang S; Xin Y
    Oncotarget; 2016 Dec; 7(49):81062-81076. PubMed ID: 27835600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YAP inhibition overcomes adaptive resistance in HER2-positive gastric cancer treated with trastuzumab via the AKT/mTOR and ERK/mTOR axis.
    Qiao J; Feng M; Zhou W; Tan Y; Yang S; Liu Q; Wang Q; Feng W; Pan Y; Cui L
    Gastric Cancer; 2024 Jul; 27(4):785-801. PubMed ID: 38782859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
    Kim HP; Han SW; Song SH; Jeong EG; Lee MY; Hwang D; Im SA; Bang YJ; Kim TY
    Oncogene; 2014 Jun; 33(25):3334-41. PubMed ID: 23873022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
    Piro G; Carbone C; Cataldo I; Di Nicolantonio F; Giacopuzzi S; Aprile G; Simionato F; Boschi F; Zanotto M; Mina MM; Santoro R; Merz V; Sbarbati A; de Manzoni G; Scarpa A; Tortora G; Melisi D
    Clin Cancer Res; 2016 Dec; 22(24):6164-6175. PubMed ID: 27267856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GM130 regulates epithelial-to-mesenchymal transition and invasion of gastric cancer cells via snail.
    Zhao J; Yang C; Guo S; Wu Y
    Int J Clin Exp Pathol; 2015; 8(9):10784-91. PubMed ID: 26617790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DDR2 Induces Gastric Cancer Cell Activities via Activating mTORC2 Signaling and Is Associated with Clinicopathological Characteristics of Gastric Cancer.
    Wang YG; Xu L; Jia RR; Wu Q; Wang T; Wei J; Ma JL; Shi M; Li ZS
    Dig Dis Sci; 2016 Aug; 61(8):2272-2283. PubMed ID: 27010547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Furin promotes epithelial-mesenchymal transition in pancreatic cancer cells via Hippo-YAP pathway.
    Zhang Y; Zhou M; Wei H; Zhou H; He J; Lu Y; Wang D; Chen B; Zeng J; Peng W; Du F; Gong A; Xu M
    Int J Oncol; 2017 Apr; 50(4):1352-1362. PubMed ID: 28259973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.
    Mohd Nafi SN; Generali D; Kramer-Marek G; Gijsen M; Strina C; Cappelletti M; Andreis D; Haider S; Li JL; Bridges E; Capala J; Ioannis R; Harris AL; Kong A
    Oncotarget; 2014 Aug; 5(15):5934-49. PubMed ID: 25153719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).
    Oliveras-Ferraros C; Corominas-Faja B; Cufí S; Vazquez-Martin A; Martin-Castillo B; Iglesias JM; López-Bonet E; Martin ÁG; Menendez JA
    Cell Cycle; 2012 Nov; 11(21):4020-32. PubMed ID: 22992620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
    Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
    BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer.
    Shi W; Zhang G; Ma Z; Li L; Liu M; Qin L; Yu Z; Zhao L; Liu Y; Zhang X; Qin J; Ye H; Jiang X; Zhou H; Sun H; Jiao Z
    Nat Commun; 2021 May; 12(1):2812. PubMed ID: 33990570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition.
    Huang D; Duan H; Huang H; Tong X; Han Y; Ru G; Qu L; Shou C; Zhao Z
    Sci Rep; 2016 Feb; 6():20502. PubMed ID: 26846307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.
    Sampera A; Sánchez-Martín FJ; Arpí O; Visa L; Iglesias M; Menéndez S; Gaye É; Dalmases A; Clavé S; Gelabert-Baldrich M; Poulsen TT; Kragh M; Bellosillo B; Albanell J; Rovira A; Montagut C
    Mol Cancer Ther; 2019 Nov; 18(11):2135-2145. PubMed ID: 31484705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition.
    Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
    Mol Cancer Ther; 2017 Jun; 16(6):1145-1154. PubMed ID: 28223426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER4 promotes the progression of colorectal cancer by promoting epithelial‑mesenchymal transition.
    Jia X; Wang H; Li Z; Yan J; Guo Y; Zhao W; Gao L; Wang B; Jia Y
    Mol Med Rep; 2020 Apr; 21(4):1779-1788. PubMed ID: 32319604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asparaginyl endopeptidase promotes the invasion and metastasis of gastric cancer through modulating epithelial-to-mesenchymal transition and analysis of their phosphorylation signaling pathways.
    Cui Y; Wang Y; Li H; Li Q; Yu Y; Xu X; Xu B; Liu T
    Oncotarget; 2016 Jun; 7(23):34356-70. PubMed ID: 27102302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCAR4 facilitates trastuzumab resistance and EMT in breast cancer via sponging miR-665 and interacting with YAP1.
    Ye X; Liu Q; Qin X; Ma Y; Sheng Q; Wu X; Chen S; Huang L; Sun Y
    FASEB J; 2024 Apr; 38(7):e23589. PubMed ID: 38572594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.